Am. J. Trop. Med. Hyg., 80(2), 2009, pp. 242-244
Copyright © 2009 by The American Society of Tropical Medicine and Hygiene
SHORT REPORT
Serologic Evidence of Human Ehrlichiosis in Peru
Pedro L. Moro,
Jyotsna Shah,
Olga Li,
Robert H. Gilman,
Nick Harris, AND
Manuel H. Moro*
Immunization Safety Office, Office of the Chief Science Officer, Centers for Disease Control and Prevention, Atlanta, Georgia; IGeneX Inc., Palo Alto, California; Laboratory of Clinical Pathology, College of Veterinary Medicine, University of San Marcos, Lima, Peru; Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland; Division of Comparative Medicine, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland
ABSTRACT
A serosurvey for human ehrlichiosis caused by Ehrlichia chaffeensis and Anaplasma phagocytophilum was performed in different regions of Peru by using indirect immunofluorescence assays (IFAs). Regions included an urban community in a shantytown in Lima (Pampas) and three rural communities located on the northern coast of Peru (Cura Mori), in the southern Peruvian Andes (Cochapata), and in the Peruvian jungle region (Santo Tomas). An overall E. chaffeensis seroprevalence of 13% (21 of 160) was found by IFA. Seroprevalences in females and males was 15% (16 of 106) and 9% (5 of 53), respectively. Seroprevalences in Cura Mori, Cochapata, Pampas, and Santo Tomas were 25% (10 of 40), 23% (9 of 40), 3% (1 of 40), and 3% (1 of 40), respectively. Seroprevalences in Cura Mori and Cochapata were significantly higher than in Santo Tomas or Pampas (P < 0.01). No sera were reactive to A. phagocytophilum. These findings suggest that human infection with E. chaffeensis occurs in Peru. Further studies are needed to characterize Ehrlichia species in Peru, their vectors and their clinical significance.
Received January 28, 2008.
Accepted for publication October 31, 2008.
Acknowledgments: We thank Dr. Sergio Recuenco (Centers for Disease Control and Prevention, Atlanta, GA) Dr. Ofelia Zegarra-Moro from (Kansas State University, Manhattan, KS), and Lilia Cabrera (A.B. Prisma, Lima, Peru) for useful advice.
Disclosure: The authors report no conflicts of interest with the study.
* Address correspondence to Manuel H. Moro, Division of Comparative Medicine, National Center for Research Resources, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892. E-mail: manuel.moro{at}nih.gov
Authors addresses: Pedro L. Moro, Immunization Safety Office, Office of the Chief Science Officer, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop D26, Atlanta, GA 30333, E-mail: pmoro{at}cdc.gov. Jyotsna Shah, and Nick Harris, IGeneX Inc., 797 San Antonio Road, Palo Alto, CA 94303, E-mails: jyotsna{at}aol.com and nharris{at}aol.com. Olga Li, Laboratorio de Patología Clínica, Facultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima, Peru, E-mail: Olgalie{at}hotmail.com. Robert H. Gilman, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room W5515, Baltimore, MD 21205, E-mail: rgilman{at}jhsph.edu. Manuel H. Moro, Division of Comparative Medicine, National Center for Research Resources, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892, E-mail: manuel.moro{at}nih.gov.
Copyright © 2009 by the American Society of Tropical Medicine and Hygiene.